AR073813A1 - Compuestos de 5, 6-dihidro-1h-piridin-2-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento o prevencion de una infeccion por el virus de la hepatitis c. - Google Patents
Compuestos de 5, 6-dihidro-1h-piridin-2-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento o prevencion de una infeccion por el virus de la hepatitis c.Info
- Publication number
- AR073813A1 AR073813A1 ARP090103904A ARP090103904A AR073813A1 AR 073813 A1 AR073813 A1 AR 073813A1 AR P090103904 A ARP090103904 A AR P090103904A AR P090103904 A ARP090103904 A AR P090103904A AR 073813 A1 AR073813 A1 AR 073813A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydro
- methanesulfonamide
- aza
- dioxo
- benzo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- -1 2-Chloro-4-fluoro-benzyl Chemical group 0.000 abstract 10
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 abstract 3
- OXRRHYRRQWIHIV-UHFFFAOYSA-N 2,3-dihydro-1h-pyridin-6-one Chemical compound O=C1NCCC=C1 OXRRHYRRQWIHIV-UHFFFAOYSA-N 0.000 abstract 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 abstract 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 abstract 2
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 abstract 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 abstract 1
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Compuestos de 5,6-dihidro-1H-piridin-2-ona y composiciones farmacéuticas que contienen dichos compuestos que son de utilidad para el tratamiento de infecciones por el virus de hepatitis C. Reivindicacion 1: Un compuesto seleccionado de (1R,2S,7R,8S)-N-{3-[3-(2-cloro-4-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1S,2S,7R,8R)-3-(3-cloro-4-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R,)-6-hidroxi-3-(3-metoxi-bencil)-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin7-il}-metansulfonamida; N-{3-[2S,7R)-3-(2,4-difluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[2S,7R)-3-(2-cloro-4-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-(2-bromo-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[2S,7R)-3-(4-fluoro-3-metoxi-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-(3-cloro-4-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[2S,7R)-3-(3,3-dimetil-butil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-(3,4-difluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-(4-fluoro-3-metil-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,4-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-bencil-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; (rac-di-exo, di-exo)-N-{3-[3-(4-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-tetraciclo[6,3,1,02,7,09,11]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}metansulfonamida, N-{3-[(2S,7R)-3-(3-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-3-ciclohexilmetil-6-hidroxi-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-6-hidroxi-4-oxo-3-tiofen-2-ilmetil-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-6-hidroxi-3-(2-metil-bencil)-4-oxo-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(2S,7R)-6-hidroxi-4-oxo-3-(2,3,4-trifluoro-bencil)-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1S,2S,7R,8R)-3-(4-fluoro-3-metil-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1S,2S,7R,8R)-(3-bencil-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1R,2S,7R,8S)-3-(3-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1S,2S,7R,8R)-6-hidroxi-4-oxo-3-(1-trifluorometil-ciclopropilmetil)-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida, N-{3-[(1S,2S,7R,8R)-3-(3,4-difluoro-bencil)-6-hidroxi-4-oxo-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida, N-{3-[(1R,2S,7R,8S)-6-hidroxi-4-oxo-3-(2,3,4-trifluoro-bencil)-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida, N-{3-[(1R,2S,7R,8S)-6-hidroxi-4-oxo-3-tiofen-3-ilmetil-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida, N-{3-[(2S,7R)-6-hidroxi-4-oxo-3-(2,4,5-trifluoro-bencil)-3-aza-triciclo[6,2,2,02,7]dodec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1R,2S,7R,8S)-6-hidroxi-4-oxo-3-tiofen-2-ilmetil-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1R,2S,7R,8S)-(3-ciclohexilmetil-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; N-{3-[(1S,2S,7R,8R)-6-hidroxi-3-(2-metil-bencil)-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida; y N-{3-[(1S,2S,7R,8R)-3-(3-fluoro-bencil)-6-hidroxi-4-oxo-3-aza-triciclo[6,2,1,02,7]undec-5-en-5-il]-1,1-dioxo-1,2-dihidro-1l6-benzo[1,2,4]tiadiazin-7-il}-metansulfonamida, o sus sales farmacéuticamente aceptables y sus solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10416308P | 2008-10-09 | 2008-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073813A1 true AR073813A1 (es) | 2010-12-01 |
Family
ID=42100977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103904A AR073813A1 (es) | 2008-10-09 | 2009-10-09 | Compuestos de 5, 6-dihidro-1h-piridin-2-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento o prevencion de una infeccion por el virus de la hepatitis c. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8129368B2 (es) |
| CN (1) | CN102176912B (es) |
| AR (1) | AR073813A1 (es) |
| TW (1) | TW201026675A (es) |
| WO (1) | WO2010042830A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10565394B2 (en) | 2012-10-25 | 2020-02-18 | Verisign, Inc. | Privacy—preserving data querying with authenticated denial of existence |
| US9202079B2 (en) * | 2012-10-25 | 2015-12-01 | Verisign, Inc. | Privacy preserving data querying |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1114823A3 (en) * | 1992-08-19 | 2001-07-18 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| AU2002365198A1 (en) | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
| US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| KR100847181B1 (ko) * | 2004-08-23 | 2008-07-17 | 에프. 호프만-라 로슈 아게 | 이종환 항바이러스 화합물 |
| WO2006066079A2 (en) * | 2004-12-17 | 2006-06-22 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
| WO2006068233A1 (ja) * | 2004-12-24 | 2006-06-29 | Nikon Corporation | 磁気案内装置、ステージ装置、露光装置、及びデバイスの製造方法 |
| WO2006115221A1 (ja) | 2005-04-21 | 2006-11-02 | Nippon Shinyaku Co., Ltd. | フタラジノン誘導体及びその医薬 |
| WO2006117306A1 (en) * | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| TW200840572A (en) * | 2006-12-12 | 2008-10-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
| UA100120C2 (en) * | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
-
2009
- 2009-10-08 TW TW098134054A patent/TW201026675A/zh unknown
- 2009-10-09 US US12/576,739 patent/US8129368B2/en not_active Expired - Fee Related
- 2009-10-09 AR ARP090103904A patent/AR073813A1/es unknown
- 2009-10-09 WO PCT/US2009/060183 patent/WO2010042830A1/en not_active Ceased
- 2009-10-09 CN CN200980140570.8A patent/CN102176912B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010042830A1 (en) | 2010-04-15 |
| HK1161684A1 (en) | 2012-08-03 |
| US8129368B2 (en) | 2012-03-06 |
| CN102176912A (zh) | 2011-09-07 |
| US20100119481A1 (en) | 2010-05-13 |
| TW201026675A (en) | 2010-07-16 |
| CN102176912B (zh) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000193A2 (es) | Compuestos antiproliferativos y métodos para utilizarlos | |
| CY1118621T1 (el) | Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων | |
| AR054799A1 (es) | Derivados de oxindol | |
| ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
| PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
| CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| PE20070135A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
| CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
| NI201000179A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
| JP2009511508A5 (es) | ||
| ECSP066950A (es) | Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2 | |
| UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| MX2010001170A (es) | Derivados de imidazolona, metodo de preparacion de los mismos y uso biologico de los mismos. | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| PA8582101A1 (es) | Indoles sustituidos en posicion 2,4 | |
| AR073813A1 (es) | Compuestos de 5, 6-dihidro-1h-piridin-2-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento o prevencion de una infeccion por el virus de la hepatitis c. | |
| JP2019504818A5 (es) | ||
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |